1) New drug pipeline activity
They’ve added a new cancer drug candidate (MTX240), which is still in early clinical stages. This expands their pipeline but doesn’t generate revenue yet.
2) Manufacturing partnership
They partnered with a company to produce material for upcoming clinical trials. This means they’re preparing to move forward with testing.
3) Progress on existing drug (eRapa)
They’ve started an early access program for one of their lead treatments targeting a rare condition. That’s a step forward—but it’s not full regulatory approval yet.
⚠️ Major concerns
1) Reverse stock split
They adjusted their share structure to keep the stock listed. This is usually a sign the price had fallen too low and often hurts investor confidence.
2) No strong revenue
Like many small biotech companies, they are still spending heavily without meaningful income.
3) High funding risk
They will likely need more cash to continue trials, which could mean issuing more shares (and further price drops).
🧠What it really means
There is progress, but it’s all early-stage and uncertain.
Meanwhile, the bigger picture investors care about is:
- survival (cash)
- dilution risk
- probability of drug success
Right now, those risks are outweighing the positives.
🧠Bottom line
Biodexa isn’t collapsing because nothing is happening—it’s falling because:
progress is slow, uncertain, and expensive… while investor patience is running out.
Comments
Post a Comment